Introduction: The socioeconomic impact of obstructive sleep apnea-hypopnea syndrome (OSAHS) is considerable. The aim of this study was to evaluate the cost-effectiveness of treating OSAHS with continuous positive airway pressure (CPAP) and the impact of CPAP compliance.
Methods: This was a retrospective, case-crossover study of 373 patients with OSAHS receiving CPAP. We compared changes in costs, Epworth score and health-related quality of life (EQ-5D questionnaires) between the year before treatment and the year after treatment. The incremental cost-effectiveness ratio (ICER) for the first year of treatment was estimated, and projections were made for the second year, using different effectiveness and cost scenarios.
Results: The visual analog scale score for the EQ-5D questionnaire increased by 5 points and the Epworth score fell by 10 points during the year of CPAP treatment. Mean gain in quality-adjusted life years (QALY) was 0.05 per patient per year (P<.001): 0.07 among compliers and -0.04 among non-compliers. ICER was €51,147/QALY during the first year of CPAP treatment and €1,544/QALY during the second year.
Conclusion: CPAP treatment in patients with moderate-severe OSAHS improves the quality of life of compliant patients, and is cost-effective as of the second year.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/j.arbres.2016.02.005 | DOI Listing |
J Med Microbiol
January 2025
Parul Institute of Applied Sciences, Faculty of Applied Sciences, Parul University, Vadodara, Gujarat 391760, India.
The rise in antimicrobial resistance poses a significant threat to global health, particularly among diabetic patients who are prone to urinary tract infections (UTIs). Pathogens that cause UTI among diabetic patients exhibit significant multidrug resistance (MDR) patterns, necessitating more precise empirical treatment strategies..
View Article and Find Full Text PDFCell Transplant
January 2025
Department of Hematology, 920th Hospital of Joint Logistics Support Force, Kunming, China.
Donor-specific antibodies (DSAs) are essential causes of graft rejection in haploidentical hematopoietic stem cell transplantation (haplo-HSCT). DSAs are unavoidable for some patients who have no alternative donor. Effective interventions to reduce DSAs are still needed, and the cost of the current therapies is relatively high.
View Article and Find Full Text PDFInt J Hematol
January 2025
Department of Blood Transfusion, Osaka University Hospital, Osaka, Japan.
Fostamatinib had superior efficacy to a placebo and acceptable safety profiles for at least 1 year in a phase 3 study of Japanese patients with primary immune thrombocytopenia. Here, we report the 3-year safety and efficacy of fostamatinib in that study. Data from 33 patients who received at least one dose of fostamatinib were analyzed.
View Article and Find Full Text PDFAnn Surg Oncol
January 2025
Department of General and Visceral Surgery, Ulm University Hospital, Ulm, Germany.
Background: Robotic hepatectomy has been increasingly adopted for the treatment of hepatocellular carcinoma (HCC). However, the ideal technique of parenchymal transection in robotic hepatectomy has been a matter of ongoing debate in literature.
Patients And Methods: In this video, we demonstrate the technique of robotic anatomical segment VIII resection using the scissor hepatectomy technique for parenchymal transection on a 75-year-old male patient with a solitary HCC lesion.
Ann Surg Oncol
January 2025
Department of Gastrointestinal Surgery, The Third Affiliated Hospital of Wenzhou Medical University, Wenzhou, China.
Background: This study aimed to develop a dynamic survival prediction model utilizing conditional survival (CS) analysis and machine learning techniques for gastric neuroendocrine carcinomas (GNECs).
Patients And Methods: Data from the Surveillance, Epidemiology, and End Results (SEER) database (2004-2015) were analyzed and split into training and validation groups (7:3 ratio). CS profiles for patients with GNEC were examined in the full cohort.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!